National Jewish Health: New Monoclonal Antibody Shows Promise for Severe Asthma
October 28, 2021
October 28, 2021
DENVER, Oct. 28 (TNSJou) -- National Jewish Health, a respiratory hospital, issued the following news release:
A new monoclonal antibody therapy shows promise in offering an alternative treatment for patients suffering from moderate-to-severe asthma. Research led by Michael E. Wechsler, MD, MMSc, director of the National Jewish Health Cohen Family Asthma Institute, found that itepekimab was safe and effective in a phase 2 trial published online today in the New England Journal of Me . . .
A new monoclonal antibody therapy shows promise in offering an alternative treatment for patients suffering from moderate-to-severe asthma. Research led by Michael E. Wechsler, MD, MMSc, director of the National Jewish Health Cohen Family Asthma Institute, found that itepekimab was safe and effective in a phase 2 trial published online today in the New England Journal of Me . . .